08-Feb-2001 - Abbott Laboratories

Abbott Laboratories Signs Agreement With MedNova and Rubicon Medical for Vascular Products

Abbott Park, Illinois, February 2, 2001 – Abbott Laboratories today announced that it has entered agreements with MedNova, Limited, and Rubicon Medical, Inc. for products that significantly expand Abbott's presence in the interventional cardiology and radiology markets.

Abbott and MedNova, Limited, based in Galway, Ireland, have entered a distribution agreement for MedNova's embolic filter and carotid stent products. Embolic capture devices, such as filters, are used to contain the fragments that break off vessel walls during interventional procedures before the embolic material can cause harm to critical organs. MedNova's first generation embolic filters, NeuroShield and CardioShield, are approved in Europe. Carotid stents are used in peripheral vascular procedures treating blockages in either of the two carotid arteries in the neck that carry blood to the brain.

Abbott also has entered an exclusive, worldwide license agreement with Rubicon Medical, Inc. headquartered in Salt Lake City, Utah, for Rubicon's Guardian system, an occlusion balloon for embolization protection. The Guardian system utilizes a balloon that is inflated during a stent procedure in the vessels that feed blood to the heart, brain, or kidneys and an aspiration catheter that is used to remove embolic material dislodged during the procedure. The Guardian system, in conjunction with the MedNova filters, will allow Abbott to offer clinicians both embolic capture technologies. Rubicon and Perclose, an Abbott subsidiary, are currently co-developing the Guardian system.

New advances in interventional medicine have created an unmet need for devices that reduce the risk of embolic debris. This issue is especially important for saphenous vein grafts, carotid artery stenting and renal artery stenting where intravascular debris dislodged during a procedure could possibly cause a stroke, heart attack or damage to the kidneys. It is estimated that embolic capture devices could be used as standard practice in carotid stenting procedures, and in approximately 10-20 percent of coronary procedures. This is a high-growth, developing market, and there are not any devices currently on the market in the United States.

"The MedNova and Rubicon agreements bring additional leading technology and innovative products to our vascular franchise," said Richard A. Gonzalez, executive vice president, medical products, Abbott Laboratories. "Through these partnerships and other recent licensing deals, Abbott is expanding its opportunities in emerging segments of vascular medicine by building on our foundation in vascular therapeutics, vascular devices with Perclose, and our existing relationships with interventional cardiologists and radiologists."

In addition to the Mednova distribution agreement, Abbott has taken an equity position in MedNova and has the option to acquire the company provided certain milestones are met. Financial terms of the agreements were not disclosed.

Abbott has recently signed several other agreements that expand the company’s vascular product line. Abbott has partnered with Biocompatibles International plc. for the development of a unique drug delivery stent and LuMend, Inc. for two peripheral catheters used to facilitate the treatment of partly occluded blood vessels, thereby minimizing the need for vascular bypass surgery. Abbott also will be conducting a study to obtain a chronic total occlusion indication for the catheters. Through Perclose, Abbott currently offers a portfolio of vascular devices, including The Closer®, The Closer S®, The Prostar>® and The Techstar®, minimally invasive devices used to automate the surgical closure of vascular punctures.

Facts, background information, dossiers
  • catheters
  • surgery
  • stroke
  • kidneys
  • Ireland
  • myocardial infarction
More about Abbott
  • News

    Francisco Partners to Acquire STARLIMS

    Francisco Partners, a leading global investment firm that specializes in partnering with technology businesses, announced that it has signed a definitive agreement to acquire the STARLIMS informatics product suite and related business assets from Abbott. Terms of the transaction were not di ... more

    Abbott Completes Acquisition of STARLIMS Technologies

    Abbott announced that it has completed its $123 million acquisition of STARLIMS Technologies Ltd. The acquisition provides Abbott with products and expertise to build its position in laboratory informatics "STARLIMS gives us access to innovative technologies and technical expertise for our ... more

    Abbott Opens New Research Facility and Pilot Plant in Ludwigshafen

    Abbott announced the opening of new development laboratories and a pilot plant facility that will research technologies and test large-scale production of newly developed drug formulations. The expansion is part of Abbott's global drug delivery business, SOLIQS, which is based in Ludwigshaf ... more

  • Products

    Lab 4.0 - Moving beyond Digitalization in the Lab

    Empower users to analyze data better, by making information more accessible and usable throughout the lab processes with STARLIMS Integrated Solution more

  • Videos

    Lab 4.0 - Moving beyond Digitalization in the Lab

    There is no doubt that technology has impacted the way labs operate, and will continue to do so. In today’s competitive landscape, organizations need to take a holistic view of their lab processes and identify areas for improvement. The future of laboratory software will evolve into more fu ... more

    Abbott Informatics Germany GmbH

    more

    Corporate Video Abbott Informatics Germany GmbH

    more

  • Companies

    Abbott Informatics Germany GmbH

    We are a leading provider of laboratory information management solutions with more than 1200 implementations in over 45 countries. Since 1987 STARLIMS has specialized in what it does best – delivering industry-leading laboratory information management solutions that enable organizations t ... more

    Abbott Informatics Europe BV

    STARLIMS, an Abbott Company, helps laboratories optimize data management, accessibility, integrity and long-term value by providing your lab with the powerful, efficient tools and support you need to achieve your goals. Our unified web-based platform includes our award-winning Laboratory I ... more